LOGIN  |  REGISTER
Amneal Pharmaceuticals
Chimerix

Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time

September 23, 2024 | Last Trade: US$2.84 0.48 20.34

NEW YORK, Sept. 23, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), will host its Investor R&D Day today in New York. The event is from 10:30 am ET to 12:30 pm ET and can be accessed virtually by clicking here

A link to the live webcast, replay and presentation slides of the event will be available on the "Events and Presentations" section of Kodiak's Investors & Media website at http://ir.kodiak.com/. A replay of the webcast will be available for a limited time following the event.

The event will feature speakers from members of the Kodiak leadership team and the following leading retina specialist key opinion leaders (KOLs):

  • David Brown, MD, Clinical Professor of Ophthalmology, Baylor College of Medicine; Director of Research, Retina Consultants of Texas, Houston, TX; Chair, Medical Leadership Board, Retina Consultants of America

  • Charles Wykoff, MD, PhD, Clinical Professor of Ophthalmology Weill Cornell Medical College, Houston Methodist Hospital; Clinical Professor of Ophthalmology, Blanton Eye Institute; Director of Research, Retina Consultants of Texas; Deputy Chair of Ophthalmology, Blanton Eye Institute

Kodiak's Investor R&D Day Agenda

  • Why Kodiak
    Victor Perlroth, M.D.

  • Science of Durability
    David Brown, M.D.

  • Science of the Enhanced Formulation
    David Brown, M.D.

  • Roundtable Discussion

  • Clinical Program Overview
    Charles Wykoff, M.D., Ph.D.

  • The Kodiak Opportunity
    Victor Perlroth, M.D.

  • Roundtable Discussion

  • ABCD Platform Preview
    Dolly Chang, M.D., Ph.D.

  • Summary and Takeaways
    Victor Perlroth, M.D.

  • Audience Q&A

About Kodiak Sciences Inc.

Kodiak Sciences (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing, and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases. We are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally.

For more information, please visit www.kodiak.com.

Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.

Recursion

Stock Quote

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page